	US 12,084,719 B2
	RNA editing as biomarkers for mood disorders test
Nicolas Salvetat, Montpellier (FR); Jean-François Pujol, Saint Mathieu de Tréviers (FR); Dinah Weissmann, Saint Mathieu de Tréviers (FR); Berengere Vire, Les matelles (FR); and Siem Van Der Laan, Cazilhac (FR)
Assigned to ALCEDIAG, Peynier (FR)
Appl. No. 16/318,790
Filed by ALCEDIAG, Peynier (FR)
PCT Filed Jul. 28, 2017, PCT No. PCT/EP2017/069250 § 371(c)(1), (2) Date Jan. 18, 2019, PCT Pub. No. WO2018/020042, PCT Pub. Date Feb. 1, 2018.
Claims priority of application No. 16181619 (EP), filed on Jul. 28, 2016.
Prior Publication US 2019/0185937 A1, Jun. 20, 2019
Int. Cl. C12Q 1/68 (2018.01); C12Q 1/6853 (2018.01); C12Q 1/6883 (2018.01)

CPC C12Q 1/6883 (2013.01) [C12Q 1/6853 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/156 (2013.01)]

8 Claims

1. An in vitro method for measuring alterations of A-to-I editing on PDE8A transcripts in a blood sample of a subject at risk for having depression, or having one or more clinical signs of depression, with or without the risk of suicide attempts, comprising:

(a) in a same cellular RNA extract obtained from the blood sample from the subject containing cells expressing PDE8A and at least one of the editing enzymes ADAR1a, ADAR1b and ADAR2, determining:

i) the PDE8A mRNA expression level, and

ii) the level of the PDE8A RNA A-to-I editing of at least one or a combination of sites that can be edited on the PDE8A gene) to give an RNA editing value; and

(b) determining the adjusted relative proportion of said RNA editing site(s) to the PDE8A mRNA expression level from the results obtained in step (a) as an adjusted editing value,

wherein the adjusted editing value=(RNA editing value×relative transcript level 100);

wherein the RNA editing value of a particular edit=100× the number of sites having that particular edit/the sum of all the edits in that site; and

wherein the relative transcript level represents the total RNA level of all transcripts for PDE8A relative to the RNA level of a housekeeping gene.